secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001178913-25-000889
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Silexion Therapeutics reports FY2024 results: net loss $16.5M, cash $1.2M, and progress on SIL204
--------------------------------------------------------------------------------

- Net loss for 2024 was $16.5 million, compared to $5.1 million in 2023.
- Cash and cash equivalents as of December 31, 2024 were $1.2 million, down from $4.6 million.
- SIL204 showed significant reduction in primary tumor and metastasis in orthotopic pancreatic cancer models.
- Company raised approximately $9.1 million in gross proceeds from financings in early 2025.
- LODER Phase 2 trial achieved 56% objective response rate in patients with KRAS G12D/V mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/0001178913-25-000889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000889/zk2532884.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-000889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer